The Thing PD-1PD-L1 inhibitor 2 Experts Is Likely To Educate You On

All adverse events (AEs) were graded according to the National Cancer Institute-Common Terminology Criteria (version 3.0) [18]. The endpoint of this study was to compare the efficacy (response rate, PFS, TTP, TTNT, and OS) and the toxicity profile (rate of grade 3-4 AEs) of these two regimens. Outcome was analyzed on an intention-to-treat basis. The Chi-square test or two-sided Fisher exact test were used to compare differences in nominal variables and the rank sum test was used for continuous variables. Time-to-event analysis was performed using the Kaplan-Meier method [19]. All comparisons were determined by the log-rank test and by the Cox proportional hazards model to estimate crude hazard ratios (HRs) and 95% confidence intervals (95% CIs). Analyses were performed using SAS software, version 9.1. Times of observation were censored http://www.selleckchem.com/products/gsk1120212-jtp-74057.html on May 2009 for Rd patients and on March, 2009 for BiRd patients. Patient characteristics are listed on Table I. Baseline characteristics were similar; the two groups were comparable with respect to the major variables known to affect outcome. A similar proportion of patients in the two groups presented with International Staging System (ISS) Stage I or II at diagnosis (80.3% vs. 74.2%, P = 0.402). In both treatment groups, 44.4% of patients received SCT http://www.selleck.cn/products/pd-1-pd-l1-inhibitor-2.html at some point during the course of the disease; 38.8% of patients in BiRd group and 34.7% of patients in Rd group received a SCT upfront, defined as part of first line treatment. Based on standard IMWG criteria, the response rate was significantly higher in BiRd patients compared with Rd (Table II). In an intention-to-treat analysis, a CR was achieved in the BiRd group in 45.8% vs. 13.9% in the Rd group, (P http://www.selleckchem.com/products/MDV3100.html achieved at least a VGPR. Median duration of treatment was longer in BiRd patients compared with Rd patients (11.8 vs. 6.0 months). Response rates, for BiRd and Rd patients who completed 6 months and 1 year of treatment, were evaluated. CRs were higher in BiRd group, but the difference was not statistically significant; VGPR rate was significantly higher for BiRd patients both after 6 months of therapy (56.7% vs. 35.0%, P = 0.033) and after 1 year (72.2% vs 44.4%, P = 0.046). The median duration of follow-up for survivors from diagnosis was 37.3 months in the BiRd group and 15.7 months in the Rd group. A similar proportion of patients was still receiving treatment at the time of analysis in the two groups (20.8% vs. 23.6%, respectively in the BiRd group and Rd group, P = 0.689).